Trastuzumab Deruxtecan in Metastatic HER2-positive Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study.

Trastuzumab deruxtecan (T-DXd) has been approved for metastatic HER2-positive gastric cancer (HER2+ mGC) since July 2022 in France, through an accelerated approval. This study aims to evaluate its real-world use. We characterized T-DXd users treated for HER2+ mGC using data from the French National Health Insurance. The cohort included 196 patients, mostly men (78.1%), with a median age of 65 years. Median overall survival reached 7.7 months (95% CI: 6.2-9.0). Patients treated with T-DXd for HER2+ mGC in the real-world showed lower outcomes than those in pivotal clinical trials, consistent with previous reports on accelerated approvals.

Informations de copyright

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.